Dr. Thierry Lambert
MD
Biography
Dr Thierry Lambert is a consultant in hematology, specialized in hemophilia and rare constitutional bleeding disorders. After having been medical director of blood transfusion service in the Bicêtre AP-HP Hospital, Paris, France until 1997, he then acted as Director of the Regional Hemophilia Treatment Center (CRTH) in the same location and was Regional Hemophilia Coordinator. He is a member of the Steering Committee of the European Hemophilia Safety surveillance (EUHASS). He is also co-chair of the international working group on prophylaxis (IPSG) and member of the scientific committee of the French Hemophilia Association (AFH), national patient organization, member of the WFH. Principal investigator or sub investigator in more than ten studies focusing on the treatment of hemophilia.
Key Publications
-
Practical aspects of extended half-life products for the treatment of haemophilia.
Lambert, T ; Benson, G ; Dolan, G ; Hermans, C ; Jiménez-Yuste, V ; Ljung, R & al
Ther Adv Hematol 2018 -
Prophylaxis re-visited: the potential impact of novel factor and non-factor therapies on prophylaxis.
Carcao, M ; Lambert, T ; Leissinger, C ; Escuriola-Ettingshausen, C ; Santagostino, E ; Aledort, L
Haemophilia 2018 -
A national French non interventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.
Lambert, T ; Rothschild, C ; Volot, F ; Borel-Derlon, A ; Trossaërt, M ; Claeyssens-Donadel, S & al
Transfusion 2017 -
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors
Jimenez-Yuste Victor Auerswald Gunter ; Benson Gary ; Dolan Gerry ;Lambert Thierry Santagostino ElenaZupancic Salek Silva
Haemophilia 2021
Key Institutions
-
Hôpital Bicêtre, APHP
Université Paris Saclay
Le Kremlin-Bicêtre, France -
Centre de Référence de l’Hémophilie
-
Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles rares
CRH, CRC-MHC
Current Positions/Chairs
-
Consultant
Partial-time
Research Interests
-
Focus on paediatric hemophilia, joint expression of hemorrhagic diseases and their treatment, and anti-FVIII inhibitors.
Research Activities
-
Principal investigator or sub investigator in more than ten studies and clinical trials focused on the treatment of hemophilia.
Publications
Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis
Authors
Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).
Citation
Haemophilia. E-Pub July 10, 2018
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators
Citation
57th American Society of Hematology Meeting 2015.
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.
Authors
Aledort L, Avila ML, Blanchette V, Lambert T and On behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.
Citation
Journal of Thrombosis and Haemostasis 2015, 13 (S2), # OR105, 134
Tertiary prophylaxis in adults: What is the rationale?
Authors
Gringeri A, Lambert T, Street A, and Aledort L. on behalf of the Adolescent/Adult Prophylaxis Study Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012 Sept; 18 (5): 722-728